Who we are
BioCurate is a bold, collaborative venture, dedicated to translating Australian medical research and delivering health and economic benefits to the world. Created jointly by two of Australia’s leading biomedical universities, the University of Melbourne and Monash University, we are operationally independent with an absolute commitment to rigorous science and partnering closely with researchers to help conquer the challenges which stand between great ideas and global impact. We can help you change the future.
We bridge the gap
Our collaborative team of global biomedical experts bridge the gap between:
Academia + Industry
Ideas + Impact
Discovery + Partnerships
Collaboration + Commercialisation
Research + Translation
Staff profiles
Meet Glenn Begley
Chief Executive Officer
Dr C. Glenn Begley is a clinical haematologist and medical oncologist, whose academic and commercial roles include board level and senior positions in Australia, the USA and the UK.
Read more about Glenn
Meet our team
Meet Damien Bates
Chief Scientific Officer Head of Translational Medicine
Dr Damien Bates is a senior healthcare industry executive specialising in global preclinical and clinical development, medical affairs, marketing authorisation and lifecycle management of biologics and devices.
Read more about Damien
Meet our team
Our team
150
Has over 150 years of combined biotech/pharma industry experience
35
Has been directly involved in over 35 Investigational New Drug applications (INDs)
70
Are responsible for 70 therapeutics currently in the clinic
$2.1B
Were directly involved in 15 deals worth a cumulative total of over $2.1 billion
Twitter feed
Dr Kate Murphy, NHMRC Career Development Fellow, the University of Melbourne
“Our interactions with BioCurate have changed the way that we view our research and is being used to inform the development and direction of current and future projects for greater impact and commercial potential.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”
Prof John Carroll, Director Biomedicine Discovery Institute, Monash University
“There is in most research environments a substantial gap in understanding as to what it takes to move from discovery to commercialisation, or even investment….and I strongly believe the single biggest impact at this stage is the experience our researchers have had discussing the process and expectations with your team….
Congratulations on everything you and your team have achieved in such a short time and in what is a completely new landscape.”
Prof John Carroll, Director Biomedicine Discovery Institute, Monash University
“There is in most research environments a substantial gap in understanding as to what it takes to move from discovery to commercialisation, or even investment….and I strongly believe the single biggest impact at this stage is the experience our researchers have had discussing the process and expectations with your team….
Congratulations on everything you and your team have achieved in such a short time and in what is a completely new landscape.”
Dr Linda Pullan, Director, Pullan Consulting, CA, USA and member of ISAG
“BioCurate brings deep industry perspective to select opportunities most likely to appeal to biotechnology and pharmaceutical companies, to confirm or extend the properties essential to entice those partners, and to communicate the science in a way that enables ready assessment of fit. This is hugely valuable to industry licensing efforts and will increase the probability of commercialization of the academic work.
I expect BioCurate to be on the top of the list of places where industry will hunt for early drug candidates.”
Penelope Lane, Senior Business Development Manager, the University of Melbourne
“Working with the team at BioCurate towards translation and commercialisation of medical research from the University of Melbourne has been a comprehensive, professional and considered experience, allowing the researchers, commercialisation teams and funds to successfully navigate investment into early stage medical research.
Collaboration of this nature is a best practice example in support of a truly innovative ecosystem for medical research.”